171 related articles for article (PubMed ID: 8983891)
1. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer.
Tsavaris N; Tentas K; Kosmidis P; Mylonakis N; Sakelaropoulos N; Kosmas C; Lisaios B; Soumilas A; Mandrekas D; Tsetis A; Klonaris C
Chemotherapy; 1996; 42(3):220-6. PubMed ID: 8983891
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Tsavaris NB; Tentas K; Kosmidis P; Mylonakis N; Sakelaropoulos N; Kosmas C; Lisaios B; Soumilas A; Mandrekois D; Tsetis A; Klonaris C
Am J Clin Oncol; 1996 Oct; 19(5):517-21. PubMed ID: 8823483
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of FEM (5-fluorouracil, epirubicin, mitomycin C) therapy for resected advanced gastric cancer. Ehime Gastric Cancer Study Meeting].
Kurita A; Takashima S; Sakakihara Y; Tsunekawa K; Matsuzaka T
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2319-24. PubMed ID: 8259845
[TBL] [Abstract][Full Text] [Related]
4. Use of 5-fluorouracil, epirubicin and mitomycin C (FEM) as adjuvant therapy in node-positive, radically-resected gastric cancer patients: survey of a general hospital experience.
Caffo O; Ambrosini G; Amichetti M; Brugnara S; Graiff C; Robbiati SF; Galligioni E
Oncol Rep; 1998; 5(6):1465-9. PubMed ID: 9769389
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
[TBL] [Abstract][Full Text] [Related]
7. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
[TBL] [Abstract][Full Text] [Related]
9. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
[TBL] [Abstract][Full Text] [Related]
10. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
12. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
[TBL] [Abstract][Full Text] [Related]
13. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
[TBL] [Abstract][Full Text] [Related]
14. [Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
Takada T; Kato H; Sasaki M; Matsushiro T; Yamauchi H; Kajihara T; Watanabe G; Hanaue H; Yoshida K; Shimizu T
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1295-301. PubMed ID: 1503483
[TBL] [Abstract][Full Text] [Related]
15. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant chemotherapy in gastric cancer. Experience at the National Institute of Nutrition].
León Rodríguez E; Domínguez A
Rev Invest Clin; 1992; 44(2):221-7. PubMed ID: 1439310
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
18. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
[TBL] [Abstract][Full Text] [Related]
19. [An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer].
Nakazato H; Koike A; Ichihashi H; Saji S; Danno M; Ogawa N
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2563-76. PubMed ID: 2505682
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
